Recap: Biomarin Pharmaceutical Q4 Earnings

Biomarin Pharmaceutical BMRN reported its Q4 earnings results on Thursday, February 22, 2024 at 04:05 PM.

Here's what investors need to know about the announcement.

Earnings

Biomarin Pharmaceutical beat estimated earnings by 113.04%, reporting an EPS of $0.49 versus an estimate of $0.23.

Revenue was up $108.67 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.24 which was followed by a 5.17% drop in the share price the next day.

Here's a look at Biomarin Pharmaceutical's past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 0.22 0.47 0.18 -0.07
EPS Actual 0.46 0.54 0.60 0
Revenue Estimate 608.33M 591.46M 570.62M 536.97M
Revenue Actual 581.33M 595.27M 596.41M 537.54M

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Guidance

Biomarin Pharmaceutical management provided guidance for FY 2024, expecting earnings between $2.6 and $2.8 per share.

To track all earnings releases for Biomarin Pharmaceutical visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMRN Logo
BMRNBiomarin Pharmaceutical Inc
$58.420.57%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
26.09
Growth
Not Available
Quality
31.42
Value
64.42
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Comments
Loading...